GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » EV-to-Revenue

Formycon AG (XTER:FYB) EV-to-Revenue : 9.94 (As of May. 16, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Formycon AG EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Formycon AG's enterprise value is €772.29 Mil. Formycon AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €77.70 Mil. Therefore, Formycon AG's EV-to-Revenue for today is 9.94.

The historical rank and industry rank for Formycon AG's EV-to-Revenue or its related term are showing as below:

XTER:FYB' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.42   Med: 14.51   Max: 269.23
Current: 9.94

During the past 13 years, the highest EV-to-Revenue of Formycon AG was 269.23. The lowest was 4.42. And the median was 14.51.

XTER:FYB's EV-to-Revenue is ranked worse than
55.04% of 1041 companies
in the Biotechnology industry
Industry Median: 8.07 vs XTER:FYB: 9.94

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-16), Formycon AG's stock price is €43.60. Formycon AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €4.85. Therefore, Formycon AG's PS Ratio for today is 9.00.


Formycon AG EV-to-Revenue Historical Data

The historical data trend for Formycon AG's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG EV-to-Revenue Chart

Formycon AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.95 15.77 17.22 31.25 11.68

Formycon AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.22 - 31.25 - 11.68

Competitive Comparison of Formycon AG's EV-to-Revenue

For the Biotechnology subindustry, Formycon AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Formycon AG's EV-to-Revenue falls into.



Formycon AG EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Formycon AG's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=772.286/77.696
=9.94

Formycon AG's current Enterprise Value is €772.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Formycon AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €77.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Formycon AG  (XTER:FYB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Formycon AG's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=43.60/4.846
=9.00

Formycon AG's share price for today is €43.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €4.85.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Formycon AG EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Formycon AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG (XTER:FYB) Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Executives
Dr. Stefan Glombitza Board of Directors
Dr. Carsten Brockmeyer Board of Directors
Dr. Nicolas Combé Board of Directors

Formycon AG (XTER:FYB) Headlines

No Headlines